Last reviewed · How we verify
SG2918
At a glance
| Generic name | SG2918 |
|---|---|
| Sponsor | Hangzhou Sumgen Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- SG2918 For Advanced Malignant Tumors (PHASE1)
- To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SG2918 CI brief — competitive landscape report
- SG2918 updates RSS · CI watch RSS
- Hangzhou Sumgen Biotech Co., Ltd. portfolio CI